Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #2053: Novel oral SHP-1 inhibitors exhibit pre-clinical anti-melanoma activities via activating immune cells

Suman Kundu, Keke Fan, Dan Lindner, Ernest Borden and Taolin Yi
Suman Kundu
The Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keke Fan
The Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dan Lindner
The Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ernest Borden
The Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taolin Yi
The Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

Protein tyrosine phosphatases, like protein kinases that have been targeted successfully with inhibitors for clinical cancer treatment, are promising cancer therapeutic targets. However, proof of concept remains to be established and research progression has been hampered by the limited number of identified phosphatase inhibitors with pre-clinical anti-cancer activity. Phosphatase SHP-1 is a key negative regulator in immune cells and an attractive target to augment anti-cancer immunity. Indeed, SHP-1 inhibitory agent SSG, which was effective at low \#956;M levels, induced IFN\#947;+ immune cells for pre-clinical anti-tumor action and is in early phases of clinical trials. To develop novel and more potent SHP-1-targeted anti-cancer agents, SHP-1 inhibitory lead compound L5 was identified from a library of 34,000 drug-like small chemicals and evaluated for its pre-clinical activities in inhibiting intracellular SHP-1, inducing IFN\#947;+ immune cells and in anti-melanoma action. L5 inhibited intracellular SHP-1 at 10 ng/ml with little effects on phosphatases SHP-2 and CD45 in Jurkat T cells. L5 induced mouse spleno-IFN\#947;+ cells in vitro, ~58-fold more effective than SSG. In vivo spleno-SHP-1 inhibition and -IFN\#947;+ cell induction were evident in L5-treated mice. Significantly, L5 inhibited (83%, p <0.002) the growth of SSG-refractory B16 melanoma tumors in mice at a tolerated oral dose (~3 mg/kg body weight) in a T cell-dependent manner whereas it failed to inhibit B16 cell growth in culture. L5 was also highly effective in inducing IFN\#947;+ cells (20-fold) in human peripheral blood in vitro in comparison to SSG (3-fold). Several analogs of L5 were identified and exhibited improved activities (~2-4 x) in inducing mouse spleno-IFN\#947;+ cells in vitro and in anti-melanoma action in mice as tolerated oral agents. The lead compounds also exhibited pre-clinical activities against colon cancer tumors. These results designate L5 and analogs as novel SHP-1 inhibitors with pre-clinical anti-cancer activities via an immune mechanism, demonstrate the potential of refining the lead compounds to develop oral therapeutics for enhancing anti-cancer immunity, and provide further supporting evidence for targeting SHP-1 in cancer treatment.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2053.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #2053: Novel oral SHP-1 inhibitors exhibit pre-clinical anti-melanoma activities via activating immune cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #2053: Novel oral SHP-1 inhibitors exhibit pre-clinical anti-melanoma activities via activating immune cells
Suman Kundu, Keke Fan, Dan Lindner, Ernest Borden and Taolin Yi
Cancer Res May 1 2009 (69) (9 Supplement) 2053;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #2053: Novel oral SHP-1 inhibitors exhibit pre-clinical anti-melanoma activities via activating immune cells
Suman Kundu, Keke Fan, Dan Lindner, Ernest Borden and Taolin Yi
Cancer Res May 1 2009 (69) (9 Supplement) 2053;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Up and Coming Targeted Biologic Strategies -- Oral Presentations - Proffered Abstracts

  • Abstract #2047: Non-genotoxic p53 activation and blockade of Bcl-2 signaling synergistically induce apoptosis in AML through induction of Noxa and Bak/Bax heterodimerization
  • Abstract #2054: Cucurbitacin B has a markedly antiproliferative effect on pancreatic cancer cells in vitro and in vivo.
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement